The Drug Enforcement Administration has issued a DEA Manufacturer Controlled Substance Registration Certificate for Imprimis Pharmaceuticals’ FDA-registered 503B outsourcing facility, the company announced in a press release.
The registration will allow Imprimis to better serve patients and health care professionals with affordable compounded formulations, the release said.
The newly certified facility is located in New Jersey.
Uncategorized